Granulomatous myositis: characteristics and outcome from a monocentric retrospective cohort study.

Granuloma Granulomatous myositis Inclusion body myositis Muscular sarcoidosis

Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
26 Jun 2024
Historique:
received: 14 03 2024
revised: 22 06 2024
accepted: 25 06 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 26 7 2024
Statut: aheadofprint

Résumé

Granulomatous myositis is a clinical-pathological entity, which has been rarely reported, mostly described in sarcoidosis. Currently, no clear and simple prognostic factor has been identified to predict granulomatous myositis evolution. The clinical, anatomopathological, imaging, and biological characteristics of 26 patients with granulomatous myositis were retrospectively collected to describe clinical presentation and outcomes of this condition. Twenty-six patients with granulomatous myositis were included (14 males) with a median age of symptom onset of 65 years. 54 % of patients presented a severe form of the disease defined as a Rankin score ≥2 at last follow-up visit or a progressive form of the disease (no improvement under treatment). Etiology were sarcoidosis (n = 14), inclusion body myositis (n = 4), autoimmune disease (n = 1), hematological malignancy (n = 1), and idiopathic (n = 6). Distal deficit and amyotrophy were more frequent among those with a severe disease. Corticosteroids led to improvement in 75 % of cases, but 66 % of responders relapsed. Methotrexate appeared as a promising second line therapy with clinical improvement in 50 % of patients, and no relapse in responders. Granulomatous myositis is often a severe and difficult-to-treat disease in which patients frequently progress towards severe disability. The presence of muscle atrophy and distal weakness appears to be frequently associated with a severe form of the disease.

Identifiants

pubmed: 39059057
pii: S0960-8966(24)00141-X
doi: 10.1016/j.nmd.2024.06.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5-13

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to declare.

Auteurs

Hippolyte Lequain (H)

Department of Internal Medicine, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France.

Nathalie Streichenberger (N)

Department of Pathology, Hôpital Pierre Wertheimer, Hospices Civils de Lyon, Université Claude Bernard-Lyon1, Lyon, France; Faculté de Médecine Rockefeller, Institut NeuroMyoGène INMG-PGNM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, INSERM U1315, Université Claude Bernard-Lyon1, Lyon, France.

Laure Gallay (L)

Department of Internal Medicine, Hôpital Édouard Herriot, Hospices Civils de Lyon, Lyon, France.

Mathieu Gerfaud-Valentin (M)

Department of Internal Medicine, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France.

Tanguy Fenouil (T)

Department of Pathology, Hôpital Pierre Wertheimer, Hospices Civils de Lyon, Université Claude Bernard-Lyon1, Lyon, France.

Maxime Bonjour (M)

Service de Biostatistique, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France.

Karine Le Roux (KL)

Department of Internal Medicine, Centre hospitalier Métropole Savoie, Aix-les-Bains, France.

Yvan Jamilloux (Y)

Department of Internal Medicine, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France.

Pascal Leblanc (P)

Faculté de Médecine Rockefeller, Institut NeuroMyoGène INMG-PGNM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, INSERM U1315, Université Claude Bernard-Lyon1, Lyon, France.

Pascal Sève (P)

Department of Internal Medicine, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France; Research on Healthcare Performance (RESHAPE), U129-INSERM, Université Claude Bernard-Lyon 1, Lyon, France. Electronic address: pascal.seve@chu-lyon.fr.

Classifications MeSH